One Case of Hepatic Injury Caused by Chemotherapy of Breast Cancer

doi:10.19803/j.1672-8629.2020.10.11

Abstract

Abstract: Objective To analyze the causes of drug-induced liver injury (DILI) in breast cancer patients during chemotherapy, in order to provide reference for workers in related fields. Methods The causes of DILI in a breast cancer patient with multiple chemotherapies were explored and the drugs that may cause liver injury were evaluated according to the guidelines for the diagnosis and treatment of drug-induced liver injury, relevant research publications and the Roussel Uclaf Causality Assessment Method(RUCAM). Results This patient's DILI could not be excluded. Considering length of drug administration and RUCAM quantitative form, the liver injury showed associations with trastuzumab, paclitaxel and cimetidine. Conclusion DILI is a dose-limiting toxicity of anti-tumor drugs. For patients with malignant tumors that require multiple cycles of chemotherapy, RUCAM quantitative form can distinguish potential DILI and improve treatment outcomes.

Key words: breast cancer, chemotherapy, drug-induced liver injury, RUCAM

CLC Number:

R969.2

SHEN Limeng, JIANG Sunmin, YAO Ying, XU Yinying. One Case of Hepatic Injury Caused by Chemotherapy of Breast Cancer[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 703-706.

References

[1] Yu LC, Mao YM, Chen CW.Diagnosis and treatment guideline on drug-induced liver injury[J]. Chinese Journal of Hepatology(中华肝脏病杂志), 2015, 23(10):1752-1769.
[2] Jia WP, Guo DH, Tian XY, et al.Analysis of 1110 Cases of Drug- induced Liver Injury in 79 Hospitals[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(8): 481-485.
[3] Yu SY, Yao Y.Expert consensus on prevention and management of Chemotherapy Drug-induced Liver Injury(肿瘤药物相关性肝损伤防治专家共识)[M]. Beijing: Peking Union medical college press, 2014:33-35.
[4] National Institutes of Health. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [EB/OL]. (2019-09-08) [2018-01-15]. https://www.ncbi.nlm.nih.gov/books/NBK548093/
[5] Ma L, Shi J F, Tong N. Study on adverse reactions of paclitaxel[J]. Chinese Pharmacy(中国药房), 2018, 29(21): 3014-3017.
[6] Weng BW.Comparison between the Weekly and Conventional 3-weekly Taxane-based Chemotherapies in Ovarian Cancers-a Meta- analysis[D]. Shandong: Shandong University, 2015.
[7] Gan G, Gu CJ.Analysis of 73 Adverse Drug Reaction/Event Reports on Liver Damage Induced by Anticancer Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2011, 8(11): 53-56.
[8] Liu YS, Zhao K, Zhang GQ.Analysis of 129 Cases of Adverse Drug Reactions Induced by Paclitaxel Injection in Patients with Breast Cancer in Our Hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2016, 13(3): 173-175.
[9] Guo XY, Zhang YF, Li XZ.Adverse Reactions of Weekly Paclitaxel Injection Regimen in Postoperative Chemotherapy of Breast Cancer[J]. Chinese Medicine and Clinic(中国药物与临床), 2013, 13(12): 1638-1639.
[10] Ishizuna K, Ninomiya J, Ogawa T, et al.Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report[J]. Journal of Medical Case Reports, 2014, 8(1):417.
[11] Vucicevic D,Carey EJ,Karlin NJ.Trastuzumab-induced hepatotoxicity: a case report.[J] .Breast Care (Basel), 2013, 8(2): 146-8.
[12] Srinivasan S, Parsa V, Liu CY, et al.Trastuzumab-Induced Hepatotoxicity[J]. Annals of Pharmacotherapy, 2008, 42(10): 1497-1501.
[13] Xie R, Zhao N, Cui YM.Trastuzumab-induced hepatotoxicity and analysis of adverse drug reaction: a case Report[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2017, 33(10): 936-938.
[14] Munoz A, Carrera S, Ferreiro J, et al.Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer[J]. Annals of Oncology, 2007, 18(12):2045-2046.
[15] Zhang XL.Analysis of 306 Cases of Cimetidine Adverse Reaction[J]. Guide of China Medicine(中国医药指南), 2014,12(21):72-73.
[16] Tan HF, Wang KR.Analysis of 20 Cases of Adverse Reactions Caused by Cimetidine[J]. China Modern Doctor(中国现代医生), 2008,46(16):100-101.
[17] Wang L, Xu T, Tang Y.Adverse Drug Reaction Induced by Cemetidine: Literature Analysis of 306 Cases[J]. Chinese Pharmacy(中国药房),2008,19(17):1347-1349.
[18] Zhang NQ.Analysis of 36 Cases of Adverse Reactions to Promethazine[J]. Chinese Journal of Rural Medicine and Pharmacy(中国乡村医药), 2012, 19(1): 46-47.
[19] Lun XQ.Analysis of 156 Cases of Adverse Reactions to Promethazine[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2006, 3(3): 135-137.
[20] Cai CJ. Clinical Analysis of 20 Cases of Adverse Reactions to Promethazine Hydrochloride[J]. Journal of Yangtze University (Natural Science Editio)(长江大学学报), 2014, 11(30): 93-93-95.
[21] The U.S. department of health and human services. Common Terminology Criteria for Adverse Events(CTCAE).V5.0.[EB/OL]. (2019-09-08)[2017-11-27]. https://ctep.cancer.gov/protocolde- velopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.